EA
RGLS

Emerald Advisers’s Regulus Therapeutics RGLS Stock Holding History

Emerald Advisers’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-107
Closed -$104K – 401
2014
Q2 		$104K Buy
107
+14
+15% +$12K 0.01% 387
2014
Q1 		$101K Buy
+93
New +$103K 0.01% 353
2013
Q4 		– Sell
-3,128
Closed -$3.54M – 361
2013
Q3 		$3.54M Sell
3,128
-2,038
-39% -$2.4M 0.2% 143
2013
Q2 		$6.08M Buy
+5,166
New +$4.91M 0.37% 95

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return

Emerald Advisers's RGLS Position: Q3 2014 in Review

Emerald Advisers sold out of Regulus Therapeutics (RGLS) in Q3 2014, closing a stake of 107 shares — an estimated $104K sold.

Emerald Advisers first reported a position in RGLS in Q2 2013 and held it in 4 quarters. The position peaked at $6.08M in Q2 2013. 49 funds tracked by Wall St. Rank hold RGLS as of Q3 2014.

  • Emerald Advisers reported no remaining Regulus Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Emerald Advisers sold 107 Regulus Therapeutics shares in Q3 2014, an estimated $104K.
  • Emerald Advisers first reported a position in Regulus Therapeutics in Q2 2013 and held it in 4 quarters.
  • Emerald Advisers's Regulus Therapeutics position peaked at $6.08M in Q2 2013.
  • 49 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2014.

Based on Emerald Advisers's 13F filing for Q3 2014, filed 28 Oct 2014.